Description:
Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-maximal inhibitory constant of 4.5 and 5.9 nM, respectively. The half-life of ruboxistaurin, which can be orally administered, is approximately 9h and that of its metabolite 16h, therefore allowing once-daily dosing. Based on data from clinicalTrials.gov, Children's Hospital Medical Center, Cincinnati plan a phase I/II trial of the effect of ruboxistaurin for its safety, tolerability, and effectiveness in treating adult patients with heart failure on June 9, 2016.
- Molecular Weight:505.01
- Purity:> 95%
Molecular Formula:
C28H28N4O3.HCl
Canonical SMILES:
CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O.Cl
InChI:
1S/C28H28N4O3.ClH/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24;/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34);1H/t18-;/m0./s1
InChIKey:
NYQIEYDJYFVLPO-FERBBOLQSA-N
Solubility:
Soluble to 20 mM in DMSO
Appearance:
Red solid
Application:
Enzyme Inhibitors
Storage: Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -42℃ for long term (months to years).
Synonyms:
Ruboxistaurin Hydrochloride; LY-333531 hydrochloride; Ruboxistaurin (hydrochloride); 169939-93-9; LY 333531 hydrochloride; LY333531 hydrochloride; Ruboxistaurin-d6 Hydrochloride; 169939-94-0 (base); Weitere Informationen finden Sie
hier